Maier W P, Derrick B M, Marks A D, Channick B J, Au F C, Caswell H T
Am J Surg. 1984 Feb;147(2):266-8. doi: 10.1016/0002-9610(84)90104-1.
This long-term follow-up study of 83 patients with Grave's disease who were treated by subtotal thyroidectomy reemphasizes the fact that postoperative hypothyroidism occurs primarily in the first postoperative year (27 percent of the study patients). In addition, there was no evidence of progressive increase in the incidence of hypothyroidism in subsequent years. Patients treated with radioactive iodine have a reported incidence of hypothyroidism of 70 percent 10 years postoperatively [4]. The 6 percent incidence of recurrent hyperthyroidism is much less than a reported incidence of 90 percent in patients treated with long-term antithyroid drugs [7]. Subtotal thyroidectomy continues to be an excellent method of treatment for patients with Grave's disease and compared favorably with both radioactive iodine and long-term antithyroid drugs.
这项针对83例接受甲状腺次全切除术治疗的格雷夫斯病患者的长期随访研究再次强调了一个事实,即术后甲状腺功能减退主要发生在术后第一年(占研究患者的27%)。此外,没有证据表明在随后几年中甲状腺功能减退的发生率会逐渐增加。据报道,接受放射性碘治疗的患者术后10年甲状腺功能减退的发生率为70%[4]。复发性甲状腺功能亢进6%的发生率远低于报道的长期服用抗甲状腺药物患者90%的发生率。甲状腺次全切除术仍然是治疗格雷夫斯病患者的一种极佳方法,与放射性碘和长期抗甲状腺药物相比具有优势。